Skip to main content
Caplight Logo









NXI Therapeutics

NXI Therapeutics

Private
BaselHealthcare & Life Scienceshttps://nxitherapeutics.com/

Last Round

Pre Seed

Jun 18, 2024

Total Funding Raised

$3.95M

Company Overview

NXI Therapeutics is a biotechnology company that develops a novel class of selective immunosuppressant drugs designed to treat autoimmune diseases and prevent organ transplant rejection.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

selective immunosuppressantcoronin 1 modulatorautoimmune diseasetransplant rejectionT cell therapyorgan transplantationanti-rejection drugscoronin 1 signaling pathwayimmunotherapystem cell transplantationpreclinical biotechdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NXI Therapeutics Comparables

Compare NXI Therapeutics with similar companies based on industry and business-model similarity.

NXI Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbolerIS Pharma
78%
Anokion
74%
Cour Pharma
71%

NXI Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedJun 18, 2024

Key People

Founding team and executive leadership

Rajesh Jayachandran

Chief Scientific Officer, Co-founder

Founding Team

Ruben Herrendorff

CEO at NXI Therapeutics

Executive Team

NXI Therapeutics Investors

Notable investors and investment history

NXI Therapeutics investors
InvestorRounds
KickfundPre Seed
JFG Life Sciences Foundation of the University of BaselPre Seed
BaseLaunchPre Seed
Venture KickPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 3, 2025

    Monthly visitors increased 87% MoM.

  • Dec 21, 2024

    Monthly visitors grew 2985% MoM, from 13 to 401.

NXI Therapeutics Filings

Explore SEC and related filing metadata, where available.

NXI Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NXI Therapeutics's valuation, stock price, and market status.

Is NXI Therapeutics a public or private company?

NXI Therapeutics is a private company.

What is the current stock price of NXI Therapeutics?

NXI Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NXI Therapeutics worth (valuation)?

Valuation information for NXI Therapeutics is not publicly available.

Can I buy NXI Therapeutics stock?

NXI Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NXI Therapeutics's last funding round?

NXI Therapeutics's most recent funding round was Pre Seed on June 18, 2024.

Who are the main investors in NXI Therapeutics?

Key investors in NXI Therapeutics include JFG Life Sciences Foundation of the University of Basel.

Will NXI Therapeutics IPO soon?

No public IPO plans have been announced for NXI Therapeutics.

How can I track NXI Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NXI Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range4
Year Founded2015
Last FundingJun 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?